Treatment of High Risk MDS: Azacitidine Trials, Immune Checkpoint Inhibitors, Allogeneic Transplant, TP53 Mutations and Iron Chelation Therapy
By
Indy Hematology Review
FEATURING
Richard Stone
By
Indy Hematology Review
FEATURING
Richard Stone
Login to view comments.
Click here to Login